跳至主要内容
临床试验/ISRCTN13489936
ISRCTN13489936已完成未知

The ameliorative potential of L-alanyl L-glutamine dipeptide in colon cancer patients receiving modified FOLFOX-6 regarding the incidence of diarrhea, the treatment response, and patients’ survival: a randomized controlled trial

Taif University0 个研究点目标入组 44 人开始时间: 2022年3月4日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
44

研究概览

简要总结

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35334570/ (added 08/04/2024)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Patients of both genders
  • 2. Aged =18 years
  • 3. Have histologically confirmed colon adenocarcinoma stage II, and III according to American Joint Committee on Cancer and the Union for International Cancer Control (AJCC-UICC); 7th Edition
  • 4. Have adequate hematological parameters (evidenced by white blood cell count = 4000/µl and platelet count = 100,000/µl).
  • 5. Have adequate renal (creatinine < 1.5 mg/dl) and hepatic functions (serum total bilirubin < 1.5 mg/dl).

排除标准

  • 1. Patients with stage IV colon cancer.
  • 2. Patients with second primary colon cancer.
  • 3. Patients with colon cancer with any other co-morbidity.

研究者

相似试验